A Novel Anti-Cancer Chemotherapeutic Agent Inhibits Glioblastoma Growth and Radiation Resistance
This potential chemotherapeutic agent to treat glioblastoma is a novel small molecule inhibitor.
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells — glioma stem cells — is responsible for glioblastoma’s tumorigenesis, treatment resistance and subsequent tumor recurrence.
A collaborative team of neuro-oncology surgeon/scientists — led by Ichiro Nakano, M.D., Ph.D., University of Alabama at Birmingham, and Maode Wang, M.D., Xi’an Jiaotong University, Xi’an, China — has discovered a unique and previously unidentified molecular mechanism that maintains glioma stem cells, and they have tested it as a potential therapeutic target in glioblastoma, using a novel small molecule inhibitor they designed and synthesized.
Click here to read more.
Winter Clinics for Cranial and Spinal Surgery
Feb. 25, 2018 - Mar. 1, 2018; Snowmass Village, Colo.
69th Southern Neurosurgical Society Annual Meeting
Feb. 28, 2018 - Mar. 3, 2018; San Juan, PR
Second International Brain Mapping Course
April 26-27, 2018; New Orleans
2018 AANS Annual Scientific Meeting
April 28-May 2, 2018; New Orleans
2018 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting
Jun. 2, 2018 - Jun. 5, 2018; Denver